Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Down 18.7% in March

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) was the target of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 447,124 shares, a drop of 18.7% from the February 26th total of 549,755 shares. Based on an average trading volume of 296,385 shares, the short-interest ratio is currently 1.5 days. Approximately 0.5% of the company’s shares are short sold.

Institutional Trading of Inventiva

A number of large investors have recently made changes to their positions in IVA. Creative Planning purchased a new position in Inventiva in the second quarter worth approximately $32,000. Virtu Financial LLC purchased a new stake in shares of Inventiva in the 4th quarter valued at approximately $60,000. XTX Topco Ltd acquired a new stake in shares of Inventiva in the 4th quarter valued at $84,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the 3rd quarter valued at $116,000. Finally, Cerity Partners LLC purchased a new stake in shares of Inventiva during the 4th quarter worth $93,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IVA. Leerink Partners began coverage on shares of Inventiva in a report on Monday, January 12th. They issued an “outperform” rating and a $12.00 price objective on the stock. Truist Financial assumed coverage on shares of Inventiva in a report on Thursday, March 19th. They issued a “buy” rating and a $13.00 target price for the company. HC Wainwright set a $24.00 price target on Inventiva and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Barclays started coverage on Inventiva in a research report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $16.56.

Inventiva Stock Up 1.2%

Shares of NASDAQ IVA traded up $0.07 during mid-day trading on Tuesday, hitting $5.55. The company had a trading volume of 954,177 shares, compared to its average volume of 261,496. The business’s 50-day simple moving average is $6.26 and its 200 day simple moving average is $5.37. Inventiva has a 1-year low of $2.85 and a 1-year high of $7.98.

Inventiva (NASDAQ:IVA) last released its earnings results on Saturday, February 14th. The company reported ($0.16) EPS for the quarter. The company had revenue of $0.01 million during the quarter. As a group, equities analysts predict that Inventiva will post -2.08 EPS for the current fiscal year.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.